Silver Book Fact

A prostate cancer vaccine, sipleucel-T immunotherapy, in men with metastatic castration-resistant prostate
cancer, reduced the risk of death by 22 percent compared to placebo, and represented a 4.2 month improvement in median survival.

Kantoff, P, C Higano, N Shore, E Berger, E Small, D Penson, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. NEJM. 2010; 363: 411-22. http://www.nejm.org/doi/full/10.1056/NEJMoa1001294

Reference

Title
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Publication
NEJM
Publication Date
2010
Authors
Kantoff, P, C Higano, N Shore, E Berger, E Small, D Penson, et al.
Pages
411-22
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Five-year Relative Survival (%) during Three Time Periods by Cancer Site  
  • As of July 2014, 18 anticancer drugs received FDA approval after being designated breakthrough therapies.  
  • “Knowing that his disease had a high cure rate, Ben Dacus felt a sense of security at a time of great uncertainty. In 1988 he was diagnosed with Hodgkin’s disease. Strangely…  
  • Pathogens cause around two million cancer cases worldwide each year. Ninety percent of these cases are attributable to Helicobacter pylori (H Pylori), hepatitis B virus (HBV), hepatitis C virus (HCV),…  
  • Baseline lung cancer screening would lead to more than 130,000 additional survivors in 2012.